JP Morgan Sec LLC Osmotica Pharma. - Osmotica Pharmaceuticals plc 8.3
RNS Number : 7531S J.P. Morgan Securities LLC 18 March 2021 Ap19 FORM 8.3 IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013 DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE 1. KEY INFORMATION
| Nameofpersondealing(Note1) | J.P. Morgan Securities LLC |
| Companydealtin | Osmotica Pharmaceuticals plc |
| Classofrelevantsecuritytowhichthe dealingsbeingdisclosedrelate(Note2) | US$0.01 ordinary shares |
| Dateofdealing | 17 March 2021 |
| Long | Short | |||||
| Number | (%) | Number | (%) | |||
| (1)Relevantsecurities | 1,733,749 2.76 | 40,624 0.06 | ||||
| (2)Derivatives(otherthanoptions) | 1,535 0.00 | |||||
| (3)Optionsandagreementstopurchase/sell | ||||||
| Total | 1,733,749 2.76 | 42,159 0.06 | ||||
| Purchase/sale | Numberofrelevantsecurities | Priceperunit(USD) (Note5) |
| Purchases (New Borrow) Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Sales Sales Sales Sales Sales Sales Sales Sales | 5,100 100 200 200 300 200 100 100 100 100 900 180 188 100 500 200 180 200 900 280 308 200 | N/A 3.4706 USD 3.4802 USD 3.4806 USD 3.4900 USD 3.4902 USD 3.5000 USD 3.5006 USD 3.5100 USD 3.5104 USD 3.5147 USD 3.5300 USD 3.5400 USD 3.5500 USD 3.4900 USD 3.5000 USD 3.5078 USD 3.5100 USD 3.5147 USD 3.5300 USD 3.5400 USD 3.5500 USD |
| Productname, e.g.CFD | Natureoftransaction (Note6) | Numberofrelevantsecurities (Note7) | Priceperunit (USD) (Note5) |
| Equity Swap |
| Productname, e.g.calloption | Writing,selling,purchasing,varyingetc. | Numberofsecurities towhichtheoptionrelates(Note7) | Exercise price | Type,e.g.American,Europeanetc. | Expiry date | Optionmoney paid/receivedperunit(Note5) |
| Productname, e.g.calloption | Numberofsecurities | Exercisepriceper unit(Note5) |
| Natureoftransaction (Note8) | Details | Priceperunit (if applicable) (Note 5) |
| Dateofdisclosure | 18 March 2021 |
| Contactname | Alwyn Basch |
| Telephonenumber | 0207 742 7407 |
| IfaconnectedEFM,nameofofferee/offerorwithwhichconnected | N/A |
| IfaconnectedEFM,statenatureofconnection(Note10) | N/A |
Recent news on RVL Pharmaceuticals
See all newsBrief: RVL Pharmaceuticals Says High Court Of Ireland Made A Winding Up Order In Respect Of Co On Feb 12
Brief: RVL Pharmaceuticals Says Co Issued Petition In Central Office Of High Court In Ireland To Wind Up Company
Brief: RVL Completes Financial Restructuring
Brief: Rvl Pharmaceuticals PLC Received Delisting Notice From Listing Qualifications Department Of Nasdaq Stock Market Llc
U.S. STOCKS ON THE MOVE-Cerevel Therapeutics, Scholar Rock, Helius